TOPICAL CYCLOSPORINE-A IN THE TREATMENT OF ANTERIOR SEGMENT INFLAMMATORY DISEASE
TOPICAL CYCLOSPORINE-A IN THE TREATMENT OF ANTERIOR SEGMENT INFLAMMATORY DISEASE
复制标题
DOI：
10.1097/00003226-199309000-00008
复制
发表时间：
1993-09-01
期刊：
影响因子：
2.8
通讯作者：
SUGAR, J
中科院分区：
文献类型：
--
作者：
HOLLAND, EJ;OLSEN, TW;SUGAR, J
局部环孢菌素A用于治疗43例皮质类固醇治疗失败的各种眼前节炎性疾病患者。局部环孢素A治疗范围为1周至43个月，平均治疗期为13个月。35例（81%）患有包括高危角膜移植术、特应性和春季角结膜炎、木样结膜炎、溃疡性角膜炎和蚕蚀性角膜溃疡在内的疾病的患者获得了有益的结果，炎症消退、减轻或预防。6例巩膜炎、眼瘢痕性类天疱疮或内皮炎患者（14%）未显示临床改善。2例患者（5%）出现明显眼部不适，不得不停药。其他患者均未出现局部副作用。这些患者中的27人进行了一系列的环孢素A血液水平和血清肌酐。这些患者均未出现可测量的药物血药浓度或肾毒性。
Topical cyclosporin A was used in the management of 43 patients with a variety of anterior segment inflammatory disorders that had failed corticosteroid treatment. Treatment with topical cyclosporin A ranged from 1 week to 43 months, with a mean treatment period of 13 months. Thirty-five patients (81%) with disorders including high-risk keratoplasty, atopic and vernal keratoconjunctivitis, ligneous conjunctivitis, ulcerative keratitis, and Mooren's ulcer had a beneficial result, with resolution, reduction, or prevention of inflammation. Six patients (14%) with scleritis, ocular cicatricial pemphigoid, or endotheliitis showed no clinical improvement. Two patients (5%) had significant ocular discomfort, and the drug had to be discontinued in them. None of the other patients developed local side effects. Twenty-seven of these patients were followed with serial cyclosporin A blood levels and serum creatinine. None of these patients developed measurable drug blood levels or renal toxicity.